Xing-Li Su

Prof. Dr. Xing-Li Su

Xi’an Medical University

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Pharmacological Research
Verified
Journal Article
Closed access
YYYue Yu
Yue Yu
XSXing-Li Su
Xing-Li Su
QQQiaohong Qin
Qiaohong Qin
YHYing Hou
Ying Hou
XZXin Zhang
Xin Zhang
YCYulong Chen
Yulong Chen

6 November 2019 in Cardiorenal Medicine
Verified
Journal Article
Open access
PDF file
MWMing Wei
Ming Wei
LGLu Gan
Lu Gan
ZLZheng Liu
Zheng Liu
LLLi Liu
Li Liu
JCJin-Rui Chang
Jin-Rui Chang
WSWanli W. Smith
Wanli W. Smith
Introduction: Vascular calcification (VC) is a complex, regulated process involved in many disease entities. So far, there are no treatments to reverse it. Exploring novel strategies to prevent VC is important and necessary for VC-related disease intervention. Objective: In this study, we evaluated whether MOTS-c, a novel mitochondria-related 16-aa peptide, can reduce vitamin D3 and nicotine-induced VC in rats. Methods: Vitamin D3 plus nicotine-treated rats were injected with MOTS-c at a dose of 5 mg/kg once a day for 4 weeks. Blood pressure, heart rate, and body weight were measured, and echocardiography was performed. The expression of phosphorylated adenosine monophosphate-activated protein kinase (AMPK) and the angiotensin II type 1 (AT-1) and endothelin B (ET-B) receptors was determined by Western blot analysis. Results: Our results showed that MOTS-c treatment significantly attenuated VC. Furthermore, we found that the level of phosphorylated AMPK was increased and the expression levels of the AT-1 and ET-B receptors were decreased after MOTS-c treatment. Conclusions: Our findings provide evidence that MOTS-c may act as an inhibitor of VC by activating the AMPK signaling pathway and suppressing the expression of the AT-1 and ET-B receptors.

1 January 2024 in Theranostics
Verified
Journal Article
Open access
PDF file
YZYan Zhao
Yan Zhao
YCYulong Chen
Yulong Chen
CGChihua Guo
Chihua Guo
PLPingping Li
Pingping Li
ZCZhao Cheng
Zhao Cheng
YWYunpeng Wang
Yunpeng Wang
Rationale: Recent evidence highlights the pivotal role of mitochondrial dysfunction in mood disorders, but the mechanism involved remains unclear. We studied whether the Hippo/YAP/14-3-3η signaling pathway mediates mitochondrial abnormalities that result in the onset of major depressive disorder (MDD) in a mouse model.

1 March 2020 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
YCYulong Chen
Yulong Chen
XSXing-Li Su
Xing-Li Su
QQQiaohong Qin
Qiaohong Qin
YYYue Yu
Yue Yu
MJMin Jia
Min Jia
LPLeilei Pei
Leilei Pei
Phenotypic switching of vascular smooth muscle cells (VSMCs) plays a key role in atherosclerosis. Hyperhomocysteinemia (HHcy) is an independent risk factor for atherosclerosis. HHcy induces phenotypic switching of VSMCs, but the mechanism is unclear. Endothelin-1 (ET-1) promotes proliferation and migration of VSMCs by inducing phenotypic switching during atherosclerosis. This review examined recent findings on the relationship between HHcy or the ET-1 system (including ET-1 and its receptors) and phenotypic switching of VSMCs as well as the molecular mechanism of HHcy-regulated ET-1 signaling. In particular, we focused on the potential mechanisms and pharmacological targets of phenotypic switching of VSMCs regulated by HHcy through ET-1 signaling.

1 November 2020 in European Journal of Pharmacology
Verified
Journal Article
Closed access
LKLingheng Kong
Lingheng Kong
FXFengmei Xiong
Fengmei Xiong
NSNa Sun
Na Sun
CXChennian Xu
Chennian Xu
YCYulong Chen
Yulong Chen
XSXing-Li Su
Xing-Li Su

1 November 2017 in Microvascular Research
Verified
Journal Article
Closed access
YCYulong Chen
Yulong Chen
HLHuanhuan Liu
Huanhuan Liu
XWXinhong Wang
Xinhong Wang
HZHongmei Zhang
Hongmei Zhang
ELEnqi Liu
Enqi Liu
XSXing-Li Su
Xing-Li Su